Assignee
KALLYOPE INC
US·6 granted patents·15 pending applications·12 citations·filing 2020–2025
Top patents by PatentIndex Score
21 records- 0196US11512065B2GPR119 agonistsKALLYOPE INC·Filed 2022·Granted Nov 29, 2022·7 cites·20 claims
- 0296US11279702B2AMPK activatorsKALLYOPE INC·Filed 2021·Granted Mar 22, 2022·4 cites·19 claims
- 0384US11851429B2AMPK activatorsKALLYOPE INC·Filed 2022·Granted Dec 26, 2023·1 cites·20 claims
- 0479US2025057831A1Compositions comprising 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid and methods of use thereofKALLYOPE INC·Filed 2024·Application pending·0 cites
- 0573US12281114B2NK3 modulators and uses thereofKALLYOPE INC·Filed 2024·Granted Apr 22, 2025·0 cites·20 claims
- 0673US2024101558A1Ampk activatorsKALLYOPE INC·Filed 2023·Application pending·0 cites
- 0772US12264171B2GPR40 agonistsKALLYOPE INC·Filed 2022·Granted Apr 1, 2025·0 cites·6 claims
- 0870US2022340599A1Ampk activatorsKALLYOPE INC·Filed 2022·Application pending·0 cites
- 0968US2025276989A1Gpr40 agonistsKALLYOPE INC·Filed 2025·Application pending·0 cites
- 1066US2023050965A1Sstr5 antagonistsKALLYOPE INC·Filed 2020·Application pending·0 cites
- 1166US2023041621A1Sstr5 antagonistsKALLYOPE INC·Filed 2020·Application pending·0 cites
- 1266US2023061736A1Gpr119 agonistsKALLYOPE INC·Filed 2022·Application pending·0 cites
- 1365US11407768B2AMPK activatorsKALLYOPE INC·Filed 2021·Granted Aug 9, 2022·0 cites·21 claims
- 1461US2023113609A1Sstr5 antagonistsKALLYOPE INC·Filed 2020·Application pending·0 cites
- 1560US2024115587A1Combination therapiesKALLYOPE INC·Filed 2023·Application pending·0 cites
- 1658US2024217983A1Gpr119 agonistsKALLYOPE INC·Filed 2022·Application pending·0 cites
- 1756US2025263410A1Nk3 modulators and uses thereofKALLYOPE INC·Filed 2025·Application pending·0 cites
- 1854US2023151037A1Gpr40 agonistsKALLYOPE INC·Filed 2021·Application pending·0 cites
- 1952US2022226298A1Gpr40 agonistsKALLYOPE INC·Filed 2020·Application pending·0 cites
- 2046US2022152164A1Gpcr combination therapiesKALLYOPE INC·Filed 2020·Application pending·0 cites
- 2146US2025270330A1Treatment of headache disorders with nk3 modulatorsKALLYOPE INC·Filed 2023·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →